Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

HC Wainwright Believes Ayala's Initial Cancer Data Is Encouraging

  • Ayala Pharmaceuticals Inc (NASDAQ:AYALAreported data from Part A of its Phase 2 (RINGSIDE) trial evaluating AL102 in patients with desmoid tumors on Tuesday. 
  • At 16 weeks, one of 13 patients treated with AL102 demonstrated an unconfirmed partial response, which HC Wainwright believes signals encouraging initial activity. 
  • HC Wainwright reiterated the Buy rating on the stock with a price target of $18.
  • The analyst says that Ayala's initial data is encouraging in the context of the clinical development landscape. 
  • Competitor SpringWorks Therapeutics Inc's (NASDAQ:SWTX) nirogacestat hadn't yet shown any responses during the 16-week timeframe. 
  • HC Wainwright awaits data on 
    • Disease control rate (DCR), as nirogacestat has shown 100% DCR in the Phase 2 trial on desmoid tumors.
    • Longer-term data for AL102 benchmarked to the 29% (5/17) responses observed by approximately 28 months in SpringWorks' Phase 2 trial.
    • Median progression-free survival as SpringWorks Phase 3 trial demonstrated a 71% reduction in the risk of progression vs. placebo.
    • Breakdown in patients treated by each of three dose levels could add context to Ayala's unconfirmed response.
  • Price Action: AYLA shares are up 8.25% at $1.18 during the market session on the last check Wednesday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.